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INTRODUCTION
INTRODUCTION
           Chronic kidney disease is characterized by a decrease in glomerular filtration rate and 
histological evidence of reduction in nephron population1. The clinical course is typically one 
of a progressive and unrelenting loss of nephron function ultimately leading to end stage renal 
disease.  Kidney failure is  the most visible aspect  of the spectrum, but it  represents  only a 
minority of the total population affected by kidney disease.
          The time between initial onset of disease and development of terminal renal failure may 
vary considerably not only between different diseases but also in different patients with similar 
disease  processes.  The  progressive  nature  of   CKD  and  the  ensuing  ESRD  is  putting  a 
substantial burden on global health resources since all modalities of treatment are expensive. 
            There are multiple causes of kidney injury that lead to the final common pathway of 
ESRD,  and  this  syndrome  is  characterized  by  hypertension,  anemia,  renal  bone  disease, 
nutritional  impairment,  neuropathy,  impaired  quality  of  life,  and  reduced  life  expectancy. 
Increasing evidence acquired in the past decades indicates that the adverse outcomes of CKD 
such as renal failure, cardiovascular disease, and premature death  can be prevented or delayed 
by early detection of CKD3. Earlier stages of CKD can be detected through laboratory testing 
only. Treatment of earlier stages of chronic kidney disease, as well as initiation of treatment of 
cardiovascular risk factors at early stages of CKD should be effective in reducing the rate of 
progression of CKD to ESRD.
    1
                  In patients with CKD, the  atherosclerotic cardiovascular disease  is leading cause 
for morbidity and mortality2. Carotid intima-media thickness (cIMT) has been used as a marker 
for early atherosclerosis  .The increased
incidence of CVD is the consequence of a high prevalence  of  both traditional risk factors, 
uremia-related,and “new factors,” such as hyperhomocysteinemia, infections (herpes virus and 
Chlamydia pneumoniae) and oxidative stress, which increases atherosclerotic risk among these 
patients.
            According to the 1999-2004 National Health and Nutrition Examination Survey 
(NHANES), the prevalence of CKD among the USA population is 15.3%. It becomes apparent 
that  the severity  of  CKD along with CVD severity  in any population makes a 'devastated' 
combination for both patients  and healthcare systems.  Approximately 50% of patients  with 
ESRD die from a cardiovascular event , which indicates a cardiovascular mortality that is 30 
times higher in dialysis patients and 500 times higher in 25- to 34-year-old ESRD patients than 
in individuals from the general population of the same age and race.
                     Previous studies have suggested that carotid intimal medical thickness can be used 
as a marker for  atherosclerosis  cardio vascular disease .Non invasive assessment of  intima 
medial thickness of carotid arteries by high resolution B – mode ultrasonography is widely 
used in observational studies and trials as an intermediate or proxy measure of generalised 
atherosclerosis. Increased intima medial thickness of carotid arteries has been associated with 
unfavourable levels of established cardiovascular risk factors, prevalent cardiovascular disease 
and atherosclerosis elsewhere in the arterial system.
          In this study we attempt to evaluate the association of increased intimal medial thickness 
with traditional and nontraditional cardiovascular risk factors in CKD patients.
         
AIMS AND OBJECTIVES
AIMS AND OBJECTIVES
          
         To study 
1.  To study the prevalence of traditional and non traditional               cardiovascular 
risk factors in patients with CKD.
2. Correlation of carotid intimal medial thickness to eGFR, traditional risk factors and 
non traditional risk factors for cardio vascular disease in patients with CKD.
4
REVIEW OF LITERATURE
REVIEW OF LITERATURE
CHRONIC KIDNEY DISEASE  
       Chronic kidney disease represents the entire spectrum of disease that occurs following the 
initiation of  kidney damage.  The introduction of  a  formal  definition for  CKD has  enabled 
standardize current medical communication, facilitate appropriate population based screening, 
and encourage timely prevention and treatment of kidney disease.
DEFINITION4
1. Kidney damage for > 3 months, as defined by structural or functional       abnormalities 
of the kidney, with or without decreased GFR, manifest      by either    
• Pathological abnormalities; or    
• Markers  of  kidney  damage,  including  abnormalities  in  the 
composition of the blood or urine, or abnormalities in         imaging     test.
2. GFR < 60 ml / min / 1.73 m2 for > 3 months, with or without kidney      damage.
       5
            The GFR is considered the best measure of overall kidney function. A GFR level below 
60 mL / minute / 1.73 m2 represents loss of one half or more of the adult level of normal kidney 
function. Normal GFR varies according to patient age, sex, and body size. The MDRD formula 
is a better estimate of GFR than those derived from 24-h urinary creatinine clearance or the 
Cockcroft-Gault formula.  The  abbreviated  MDRD formula  requires  age,  gender,  race,  and 
serum creatinine.
The Abbreviated MDRD Formula5
eGFR = 186 × ([SCR/88.4]–1.154) × (age) –0.203 × (0.742 if female) × (1.210 if            African-
American)
where 
eGFR = estimated glomerular filtration rate (ml/min/1.73m2), 
SCR = serum creatinine concentration (μmol/L), and age is expressed in           years 
AGE
           In young adults, the normal GFR is approximately 120 to 130 ml /minute / 1.73 m2 and 
declines  with  age.6  A decreased  GFR in  an  elderly  patient  appears  to  be  an independent 
predictor of adverse outcomes such as mortality and cardiovascular disease7,8. Because of the 
age-related  decline  in  GFR,  the  prevalence  of  chronic  kidney  disease  increases  with  age; 
approximately 17 percent of persons older than 60 years have an estimated GFR of less than 60 
mL / minute / 1.73 m2.
GENDER
              Male gender has been recognized as an important  factor in the development of CKD9. 
Gender-based genetic variability has been linked to differences in BP in both black10 and white 
individuals11.  Males  may  be  more  susceptible  to  CKD,  which  would  explain  the  higher 
proportion in renal replacement therapy programmes. In contrast to testosterone, 12,13 estrogens 
may attenuate CKD progression by lowering the cardiovascular stress response to adrenergic 
stimuli14. 
            Chronic kidney disease is a national public health problem   beset by inequities in 
incidence, prevalence, and complications across race/ethnicity, and socioeconomic status. 
SOCIOECONOMIC STATUS
           In U.S, geographic analyses have revealed community-level   poverty was strongly 
associated with higher ESRD incidence but was a more powerful predictor for black than for 
white individuals.15  Racially divided communities may share low-income status but often differ 
in wealth, community assets, exposure to heavy metals or excess ambient air particulate matter, 
and other variables that may influence CKD-related outcomes.16
RACE
             Racial factors also have a role in the susceptibility to CKD as shown by high 
prevalence  of  CKD related  to  hypertension,  diabetes,  or  both,  among  Africans  and  native 
Americans in USA as well as Afro-Caribbean and Asian individuals in UK.17 In U.S, ESRD 
rates in minorities ranged from 1.5 to 4 times those of age-adjusted counterparts, despite similar 
rates for the early stages of CKD.1
STAGING OF CHRONIC KIDNEY DISEASE
           As patients pass through the continuum of progressive kidney  damage, there are 
predictable complications, such as the development of anemia, and an elevated parathormone 
levels  and  predictable  management  issues  such  as  dialysis  access  preparation.  The  NKF/ 
KDOQI staging system4 for CKD was developed to address this need. 
 Stage  1:  Kidney  damage  (pathological  abnormalities  or  markers  of  damage  including 
abnormalities in blood or urine tests or in imaging studies) with normal or raised glomerular 
filtration rate (≥ 90 ml/min/1.73 m²)
Stage 2: Glomerular filtration rate 60 – 89 ml/min/1.73 m² with evidence of kidney damage
Stage 3: Glomerular filtration rate 30 – 59 ml/min/1.73 m²
Stage 4: Glomerular filtration rate 15 – 29 ml/min/1.73 m²
Stage 5: End-stage renal failure, glomerular filtration rate
< 15 ml/min/1.73m²
EARLY KIDNEY DISEASE – STAGES 1 AND 2
            For stages 1 and 2, kidney damage is detected by a ratio of greater than 17 mg of 
albumin to 1 g of creatinine in men or greater than 25 mg of albumin to 1 g of creatinine in 
women on two untimed (spot) urine tests.  The key issue in this group of patients becomes 
identification of whether renal function is likely to decline. The patients who at significant risk 
of  progressing19  include  proteinuria  >1  g/day20,  poorly  controlled  blood  pressure, certain 
underlying diagnoses like diabetic nephropathy, should be promptly evaluated and managed to 
decrease the risk of progression to End Stage Renal Disease (ESRD).
STAGE 3 CKD 
          Patients with stage 3 CKD have significant renal impairment and are probably the very 
group in whom renal failure is poorly recognised.21 In patients with progressive renal failure, it 
is  desirable to institute treatment to delay the need for dialysis.  There is  good evidence to 
support the efficacy of such measures in proteinuric patients.22,23 The natural history of renal 
impairment in non-proteinuric patients, however, is not well-defined, and will depend at least in 
part on the underlying cause of renal damage. The large majority of these patients will  not 
progress  sufficiently  to  require  dialysis.24 However,  patients  with  stage  3  CKD  have 
substantially increased cardiovascular risk compared to patients with better renal function, with 
43–100% increased risk of cardiovascular events25  and most of them will  die as a result of 
cardiovascular disease before ever needing dialysis.26 Increased cardiovascular risk appears to 
start  increasing  as  GFR declines  below 75  l/min/1.73 m2. 27 Management  revolves  around 
vigorous treatment of  hypertension, particularly with blockade of the renin-angiotensin system, 
to a blood pressure <130/80 mmHg (<125/75 mmHg if proteinuria >1 g/day is present), and 
treatment of other cardiovascular risk factors.
STAGE 4 AND 5
               These patients have marked disruption to normal physiology, causing complications 
such as renal anemia and renal osteodystrophy that require specialist management. These are 
also the stages at which preparations for dialysis and transplantation are required. Late referral 
of  patients  with  advanced  renal  failure  to  nephrologists  compromises the  preparations  for 
dialysis and subsequent survival of those patients28 and is more costly than timely referral.29 
Even patients who are unsuitable for dialysis (or are unwilling to undergo it) will benefit from 
management of their anemia and bone disease, and potentially from palliative care.30   
         Kidney failure is defined as a GFR below 15 ml / minute / 1.73 m2, usually accompanied 
by signs and symptoms of uremia, or as the need for initiation of kidney replacement therapy 
for management of the complications of a decreased GFR. In the United States, approximately 
98 percent of patients begin dialysis when their GFR falls below 15 ml /minute / 1.73 m2. 31
          The number of patients with end stage renal disease is growing worldwide. About 20-30 
patients have some degree of renal dysfunction for each patient who needs renal replacement 
treatment.32  Diabetes and hypertension are the two most common causes of end stage renal 
disease  and are  associated  with  a  high  risk  of  death  from cardiovascular  disease.33  Early 
detection and treatment often can prevent or delay some of these adverse outcomes.34  However, 
opportunities for prevention may be lost because chronic kidney disease is not diagnosed or is 
treated insufficiently35,36 due to lack of uniform application of simple tests for the detection and 
evaluation of the disease.37 
RISK FACTORS FOR CHRONIC KIDNEY DISEASE AND ITS 
OUTCOMES4
Type Definition Examples
Susceptibility 
factors
Factors that increase 
susceptibility to kidney 
damage
Older age, family history of chronic 
kidney disease, reduction in kidney 
mass, low birth weight, racial or 
ethnic minority status, low income 
or educational level
Initiation 
factors
Factors that directly initiate 
kidney damage
Diabetes mellitus, high blood 
pressure, autoimmune diseases, 
systemic infections, urinary tract 
infections, urinary stones, 
obstruction of lower urinary tract, 
drug toxicity
Progression 
factors
Factors that cause 
worsening kidney damage 
and faster decline in kidney 
function after kidney 
damage has started
Higher level of proteinuria, higher 
blood pressure level, poor glycemic 
control in diabetes, smoking
End-stage 
factors
Factors that increase 
morbidity and mortality in 
kidney failure
Infection, cardiovascular factors, 
anemia, low serum albumin level, 
late referral for dialysis
RISK FACTORS FOR CKD
DIABETES
               In the United States, diabetic kidney disease is the most common cause of kidney 
failure. It accounts for nearly 45% of all new cases of ESRD starting renal replacement therapy 
between  1996  and  2006.  Its  earliest  manifestation  is  microalbuminuria  with  a  normal  or 
elevated  GFR.  Effective  control  of  blood  glucose  and  blood  pressure  reduces  the  renal 
complications of diabetes. Meticulous control of blood glucose has been conclusively shown to 
reduce the development of microalbuminuria by 35% in type 1 diabetes (Diabetes Control and 
Complications Trial)39 and in type 2 diabetes (United Kingdom Prospective Diabetes Study).40 
Other studies have indicated that glycemic control can reduce the progression of diabetic renal 
disease.41
Adequate control of blood pressure with a variety of antihypertensive agents, including 
angiotensin  converting  enzyme  inhibitors,  has  been  shown  to  delay  the  progression  of 
albuminuria in both type 1 and type 2 diabetes42,43 Recently, angiotensin receptor blockers have 
been shown to have renoprotective effects in both early and late nephropathy due to type 2 
diabetes.44 
HYPERTENSION 
          Hypertension is  the second most  common cause of  ESRD in the  United States, 
accounting for 23% of incident ESRD patients between 1996 and 2000.45 Hypertension is a 
well established cause, a common complication, and an important risk factor for progression of 
renal  disease.  Controlling  hypertension  is  the  most  important  intervention  to  slow  the 
progression  of  renal  disease.  Angiotensin  converting  enzyme  inhibitors  are  particularly 
effective in slowing progression of renal insufficiency in patients with and without diabetes.46 
Angiotensin  receptor  blockers  have  a  renoprotective  effect  in  diabetic  nephropathy, 
independent of reduction in blood pressure.50 
              Non-dihydropyridine  calcium channel  blockers also have a  role  in  retarding 
progression of renal insufficiency in patients with type 2 diabetes. Early detection and effective 
treatment  of  hypertension  to  target  levels  is  essential. Hypertension  is  the  most  common 
complication of CKD. Hypertension is more difficult to control in patients with CKD. In one 
study, only 11% of CKD patients had BP levels lower than 130/85 mm Hg; 27% of these 
patients had a BP that was lower than 140/90 mm Hg; and 62% of them had a BP that was 
higher than 140/90 mm Hg.48
 
PROTEINURIA
            Proteinuria, previously considered a marker of renal disease, is itself pathogenic and is 
the single best predictor of disease progression. Reducing urinary protein excretion slows the 
progressive  decline  in  renal  function  in  both  diabetic  and  non-diabetic  kidney  disease. 
Angiotensin blockade with angiotensin converting enzyme inhibitors or angiotensin receptor 
blockers is more effective at comparable levels of blood pressure control than conventional 
antihypertensive  agents  in  reducing  proteinuria,  decline  in  glomerular  filtration  rate,  and 
progression to end stage renal disease.49 
DYSLIPIDEMIA
             Lipid abnormalities may be evident with only mild renal impairment and contribute to 
progression of  chronic  renal  disease  and increased  cardiovascular  morbidity  and mortality. 
Hydroxymethyl glutaryl coenzyme  A reductase inhibitors (statins) decreased proteinuria and 
preserved  glomerular  filtration  rate  in  patients  with  renal  disease,  an  effect  not  entirely 
explained by reduction in blood cholesterol.50
HYPERURICEMIA
            A link between hyperuricemia and the  development of systemic hypertension, 
cardiovascular disease, and renal disease has also been postulated.51
OBESITY 
             Obesity has been associated with initiation and progression of glomerulonephritis.52,53 
Among NHANES III participants, the risk of either incident ESRD or kidney disease related 
death was independently a body mass index greater than or equal to 35 kg/m2.54 Obese people 
were more likely to have a decrease in estimated GFR.55
CIGARETTE SMOKING
              Cigarette smoking has been implicated in initiation as well as progression of CKD. 
The incidence of ESRD was increased by 5.9 times among heavy smokers (>15 pack years).56 
In another study, heavy smokers (> 20 pack years) had a risk of developing albuminuria three 
times  that  of  non-smokers.57 Smoking  cessation  alone  may  reduce  the  risk  of  disease 
progression  by  30%  in  patients  with  type  2  diabetes.58 Smoking  increases  the  risk  of 
cardiovascular events in men with kidney disease.59
ALCOHOL 
            Regular and heavy (> two drinks daily) consumption of alcohol might also increase the 
risk of ESRD.60
COMPLICATIONS OF CHRONIC KIDNEY DISEASE
ANEMIA
             Anemia of chronic renal disease begins when the glomerular filtration rate falls below 
30-35% of normal and is normochromic and normocytic. This is primarily caused by decreased 
production  of   erythropoietin  by  the  failing  kidney,62 other  factors  contributing  to  anemia 
include inhibitors of erythropoiesis, shortened RBC life span, platelet dysfunction, decreased 
iron  intake,  and  secondary  hyperparathyroidism.  Anemia  is  an  independent  predictor  of 
mortality and has also been associated with increased morbidity in CKD. Correction of anemia 
improves the quality of life, cognitive and sexual function, reversal of ST-T changes on ECG, 
and reversal as well as prevention of left  ventricular hypertrophy, reduces the frequency of 
heart failure and hospitalization among patients receiving dialysis.63,.
                The risk of coronary heart disease (CHD) increases when the anemia is not treated, 
and  recent  studies  have  indicated  that  anemia  in  patients  with  chronic  renal  failure  may 
predispose to ischemic heart disease, heart failure, and premature death  Therefore, the risk of 
CHD may be distinctly  higher  in people with renal  insufficiency and concomitant  anemia, 
when compared with people with renal insufficiency but without anemia and with people with 
normal renal function64. A significant proportion of patients have established cardiovascular 
complications on initiation of dialysis, raising the possibility of early correction of anemia as a 
strategy for preventing cardiovascular co-morbidities among renal patients . It is thought that 
anaemia can increase the severity of heart failure and is associated with a rise in mortality, 
hospitalization and malnutrition. Anaemia can also further worsen renal function and cause a 
more  rapid  progression  to  dialysis  than  is  found  in  patients  without  anaemia  65.  Partial 
correction of anemia with recombinant  human erythropoietin  likely reduces  left  ventricular 
mass  and volume.  Complete  correction of  anemia may prevent  progressive  left  ventricular 
dilatation in patients with normal left ventricular volumes. In the present work we aimed to 
consider  the adverse effects.Whether anemia accelerates the progression of renal  disease is 
controversial.  Treatment  of  anemia  with  recombinant  human  erythropoietin  may  slow 
progression of chronic renal disease.
       Both National Kidney Foundation and European best practice guidelines recommend 
evaluation of anemia when hemoglobin is <11 g/dl and consideration of recombinant human 
erythropoietin  to  maintain a  target  hemoglobin of  >11 g/dl.66 But  when The United States 
Normal  Hematocrit  study  evaluated  1,233  hemodialysis  patients  with  clinical  evidence  of 
congestive  heart  failure  or  ischemic  heart  disease,  the  risk  ratio  (for  death  and  non-fatal 
myocardial  infarction)  was  1.3  for  the  normal  hematocrit  group  as  compared  to  the  low 
hematocrit .
 LIPOPROTEIN  (a )
             Elevated plasma Lpa level in chronic renal failure patients has been associated with a 
frequency distribution of apolipoprotein (a) (APOa) isoforms; similar to those found in the 
general population. This indicates that elevated LPa level in these patients is not due to genetic 
variation.  Therefore,  it  has  been  suggested  that  kidneys  have  an  important  role  in  LPa 
metabolism, decrease LPa catabolism or increase liver production.  Increased LPa levels could 
be a contributing factor in the increased incidence of atherosclerotic disease observed in CKD 
and hemodialysis patients.   Subtle structural changes such as thickening of arterial intima-
media complex thickness (IMT) occur  early  in the atherosclerotic  disease process.  B-mode 
ultrasonography is a safe and noninvasive tool for assessing early atherosclerosis and to study 
superficial vascular districts, such as the carotid or femoral artery. Indeed carotid arteries are an 
accessible  area  for  studying  the  progression  of  atherosclerotic  lesions  from onset  to  fully 
developed plaque.  Carotid  IMT measurements  are  strongly  related to  the  extent  of  athero-
sclerosis in other vascular districts too.  Consistent with their accepted role in atherogenesis, 
many known and conventional risk factors have been shown to be significantly associated with 
increased arterial wall thickness. However, much less is known about the effects of LPa on 
IMT of CKD and hemodialysis group67
HYPERPHOSPHATEMIA AND HYPERPARATHYROIDISM
             Hyperparathyroidism is one of the earliest manifestations of impaired renal function,68 
found in patients with a glomerular filtration rate of 60 ml/min.69 Parathormone is a major 
uremic  toxin  that  causes  bone  disease,  metastatic  calcification,  pruritus,  encephalopathy, 
peripheral  neuropathy,  anemia,  sexual  dysfunction,  and  hyperlipidemia.  Control  of   serum 
phosphate levels is a central goal in the management of chronic renal failure. Precipitation of 
calcium phosphate in renal tissue begins early, may influence the rate of progression of renal 
disease, and is closely related to hyperphosphatemia and calcium phosphate product. This plays 
a pivotal role in vascular calcification, CVD, calciphylaxis, and death. A calcium-phosphorus 
product  greater  than 72 mg2/dL70 is  associated with a 34 percent   increase  in  mortality  as 
compared to a product of 45 to 52 mg2/dL.71 
             Elevated serum phosphate is an independent risk factor for death due to cardiovascular 
events by enhancing vascular calcification of  atherosclerotic plaques and increased myocardial 
calcification. Patients with serum phosphate levels greater than 6.5 mg/dl have a 41% greater 
risk of  death resulting from coronary artery disease and a 20% greater risk of sudden death as 
compared with patients with serum phosphate levels between 2.4 and 6.5 mg/dl after adjusting 
for several known mortality risk factors.68
 
MALNUTRITION
                The prevalence of hypoalbuminemia is high among patients beginning dialysis, is of 
multifactorial  origin,  and  is  associated  with  poor  outcome.  Hypoalbuminemia  may  be  a 
reflection  of  chronic  inflammation  rather  than  of  nutrition  in  itself.  Spontaneous intake  of 
protein  begins  to  decrease  when  the  glomerular  filtration  rate  falls  below  50  ml/min. 
Progressive decline in renal function causes decreased appetite, thereby increasing the risk of 
malnutrition.
CARDIOVASCULAR DISEASE
               The prevalence, incidence, and prognosis of clinical cardiovascular disease in renal 
failure is not known with precision, but it begins early and is independently associated with 
increased cardiovascular and all cause mortality. 
RISK FACTORS ASSOCIATED WITH CARDIAC DISEASE73
Traditional
Age                                               Gender                            Race
Smoking                                       Diabetes                          Body mass index
Hypertension                                Dyslipidemia                  Left ventricular   
                                                                                             hypertrophy
CKD-related risk factors
Anemia                                  Calcium phosphate        Cytokines
Electrolyte imbalance            Malnutrition                  Hypoalbuminemia
Inflammation                         C-reactive protein         Endothelial activation                
Prothrombotic factors            Increased oxidative stress 
Hyperhomocysteinemia        Advanced glycation end-products
Therapy-related
Dialysis                                      Transplant– Acute rejection 
                                                                    – Immunosuppressives
             Cardiac disease, including left ventricular structural and functional 
disorders,atherosclerosis ,arteriosclerosis is an important preventable and potentially treatable 
comorbidity of early kidney disease.74 Patients with chronic kidney disease should be 
considered in the "highest risk" group for cardiovascular events75 and appropriately managed.
       Atherosclerosis of coronary arteries is the primary cause of ischaemic heart disease in 
patients with CKD, with acute myocardial infarction accounting for 20% of all cardiac deaths. 
The coronary plaque in dialysis patients is a more advanced and complex lesion, characterised 
by greater degrees of medial thickening and calcification.However, a significant number (27 - 
50%) of patients with ESRD who experience angina do not have large-vessel disease. Here, 
microvascular atherosclerosis, severe LVH and anaemia are thought to be the causative factors. 
Vascular remodelling is a pathological hallmark of CKD, affecting the large arteries as well as 
the coronary vessels. In part, this is due to medial calcification, which reduces compliance and 
manifests as an increase in pulse pressure with systolic hypertension.This process contributes to 
aortic stiffness, LVH and myocardial infarction, and parallels the increase in cardiovascular 
morbidity and mortality in the CKD patient.
           In addition to the traditional risk factors, accelerated atherosclerosis peculiar to CKD 
involves the three related processes of vascular inflammation, oxidative stress and vascular 
calcification, all of which result in vascular remodelling. Oxidative stress has a central role in 
the pathogenesis of atherosclerosis and CKD is associated with an imbalance favouring pro-
oxidant over antioxidant systems, contributing to the increased atherosclerotic burden. Serum 
C–reactive protein (CRP) is a reliable marker of atherosclerotic complications. Both CRP and 
thrombogenic factors,  such as fibrinogen, are also elevated in patients with ESRD, and are 
strong predictors of death and adverse cardiovasular events. Declining renal function itself is 
also associated with an inflammatory response, manifested by an increase in proinflammatory 
cytokines in both early and advanced CKD. Increased levels of the proatherogenic cytokine, 
IL-6, are independently associated with carotid atherosclerosis and predict mortality in dialysis 
patients.
              Therefore, coronary angiography remains the gold standard for the detection of 
epicardial CAD, but complication  rates tend to be higher among the CKD population. These 
include  contrast  nephropathy,  atheroembolism,bleeding  complications  and  contrast-induced 
pulmonary oedema. In the predialysis patient undergoing coronary angiography, the risk may 
be enough to precipitate ESRD as a result of the procedure.
TREATMENT PRINCIPLES
1. Hypertension is both a cause and a complication of chronic kidney               disease and 
should be carefully controlled in all patients 
2. Treatment of co morbid conditions, interventions to slow progression of kidney disease, 
and measures to reduce the risk for CVD should  begin during stage 1 and stage 2. 
3. Evaluation and treatment of  other complications  of  decreased GFR, such as anemia, 
malnutrition, bone  disease,  neuropathy,  and  decreased  quality  of  life,  should be 
undertaken during stage 3,  as prevalence of these complications begins to rise when 
GFR declines to less than 60 ml/min per 1.73 m2. 
4. Preparation for kidney replacement therapy should begin during stage 4, well before the 
stage of kidney failure. 
5. Initiation of dialysis and transplantation is triggered by the onset of uremic symptoms. 
Preparations  for  these  treatments  should  begin when  GFR  declines  to  less  than  15 
ml/min per 1.73 m2 (stage 5).
B MODE IMAGING
Ultrasound imaging is done “pulse echo techniques”.  An ultrasonic transducer is placed 
in contact with the skin.  The transducer repeatedly emits brief pulses of sound at a fixed rate 
called the pulse repetition sequencing.  After transmitting each pulse, the transducer waits for 
the echoes from the interfaces along the sound beam path.  Echo signals picked up by the 
transducer are amplified and processed into a format suitable for display.  The distance to a 
reflector is determined from the arrival time of its echo.  Thus d=ct/2 where d is the depth of 
the interface.  T is the echo arrival time and c is the speed of sound in tissue76.  The factor 2 
accounts for the round trip journey of the sound pulse and echo.  The aforementioned equation 
is called the range equation in ultrasound imaging.  The speed of sound 1540m/s is assumed in 
most scanners when calculating and displaying reflector depths from echo arrival times.  The 
corresponding echo arrival time is 13mcs/cm of distance of the reflector to create images pulses 
of image are transmitted along various beam lines.  Each followed by reception and processing 
of resultant echo signals. 
          Imaging is done with transduces arrays where echo signals are acquired by individual 
elements and are combined within a beam former into a single for each beam line.  Following a 
beam former, echo signal processing for imaging consists of amplifying the signals; applying 
time  gain  compensation  to  offset  the  effects  of  beam  attenuation;  applying  nonlinear 
logarithmic amplification to compress the wide range of echo signal amplitudes into a range 
that can be displayed effectively into a monitor; demodulation which forms single spike like 
signal for each echo; and B mode processing.  The B mode display is used in imaging77.  
Sclerotic and ageing changes in all cardiovascular stem of human is well reflected by the 
status  and  structure  of  arteria  carotis78.   This  artery  is  well  accessible  by  ultrasonic 
investigation   is  the  main  vessel  supplying  blood  to  the  brain.   Therefore,  ultrasonic 
investigation of arteria carotis (AC) has been the target of numerous attempts.  Findings in the 
structure of AC walls are very actual in anticipating of possible changes of coronary arteries, 
especially when there are no other symptoms of coronary ischemia79.  AC wall structure and 
thickness are good indicators for estimation of risk for stroke and myocardial infarction.  There 
are many additional relations established between AC state from one side and diabetes, high 
blood pressure,  early  sclerosis  overweight  and other  pathologies  from the  other.  The main 
changes in AC can be observed in the wall structure, which in its turn can be roughly divided 
into inner layer, contacting with blood (intima), middle layer of the wall (media) and outer 
layer (adventitia)80. 
            Intima and media thickness (IMT) is recognized to be one of the most informative 
parameters for differential diagnosis.  Changes in thickness are observed well in advance of 
sclerotic plaque appearance, thus enabling early diagnosis of sclerosis.  Sclerotic damage of 
vascular system manifests  itself  by thickening of  intima layer which is  thin for young and 
healthy persons.  Media of the AC wall consists mainly from spiral fibres of muscles and also 
is dependent on ability of arteries to support  the blood flow and to react on stress factors. 
Ultrasonography of AC including measurement of intima and media thickness is a good mean 
for  ischemic  disease  prediction,  diagnosis  and  treatment  control81.   The  main  problem  in 
diagnostics  of  the  state  of  AC  is  insufficient  precision  of  intima and  media  thickness 
measurements,  since  this  defines  all  diagnostic  reliability.   Two  layers  are  to  be  clearly 
separated  because  high  blood  pressure  causes  thickening  (hypertrophy)  of  media, while 
arteriosclerosis  causes  hypertrophy  of  intima.  For  differential  diagnosis  therefore  is  very 
important clear distinction of two layers as well as accurate measurement of absolute thickness.
Structure of carotid artery and acoustical model
Prior to ultrasonic investigation of structure of AC walls anatomical structure should be 
related to the acoustical model.  Ultrasonic echoscopy is based on reflection and scattering of 
incident ultrasonic pulses by changes of acoustical impedance of the object under investigation. 
Relation  between  anatomic  and  acoustic  layers  (changes  in  acoustic  impedance)  was 
established  and  potential  possibility  to  measure  thickness  was  proven  Since  an  ultrasonic 
transducer beam hits the artery from one side zones of adventitia, media intima, consequently 
causes reflections82.  
             More convenient for thickness measurements are the AC wall on the far side from the 
transducer.  Both walls can be measured simultaneously, or the high frequency transducer can 
be effectively used near wall of artery.  The far wall has better reflections due to the interface 
blood-intima-media-adventita acoustics  impedance sequence.  Since an ultrasonic  transducer 
beam hits the artery from one side zones of adventitia, media, consequently causes reflections. 
More  convenient  for  thickness  measurements  are  the  AC  wall  on  the  far  side  from  the 
transducer.  Both walls can be measured simultaneously, or the high frequency transducer can 
be effectively used near wall of artery.    Common Carotid artery (before it’s bifurcation on its 
are usually used for carotid artery examinations. upper end) is accessible within about 10 cm 
along the artery.
          Therefore, longitudinal variances of intima-media thickness can be measured or (with 
some assumptions) longitudinal information can be used for averaging of measurement results. 
Anyway,  repeatable  measurements  raise  the  accuracy83.   The  general  purpose  echoscopy 
systems are usually used for the arteria carotis examinations.  It is because the 7 – 8 MHz linear 
scanning transducers are suitable for such investigations.  
Both A and B scanning methods can be used for ultrasonic investigations.  B scan is used more 
frequently, since it gives overall view of the artery and general picture can be obtained for a 
quite long segment of the vessel.
Median population values of intima-media thickness range between 0.5 – 0.9 mm.  IMT 
is thickening with age with 0.01 to 0.3 mm per year.  The theoretical axial resolution of a 7 
MHz transducer is about 0.3 mm.  If IMT is thinner than 0.3 mm, the two echo interfaces 
cannot be clearly separated.  If IMT is thicker than 0.3 mm, thickness can be measured directly.
Overall thickness of intima and media layers is the most important diagnostic parameter. 
However,  thickness  of  separate  layers  would  be  useful  for  some  kinds  of  pathological 
differentiation.  Since boundary between media and  intima isn’t well demarcated in terms of 
acoustic parameters, in most cases intima-media layer thickness is taken into consideration.
B-mode ultrasound is a noninvasive method of examining the walls of peripheral arteries 
and provides measures of intima-media thickness (IMT presence of stenosis and presence of 
plaques.  The IMT corresponds to the intima media complex, which comprises endothelial 
cells,  connective  tissue  and  smooth  muscle  and  is  the  site  of  lipid  deposition  in  plaque 
formation.
In healthy adults, IMT ranges from 0.25 to 1.5 mm and values above 1.0 mm are often 
regarded as abnormal.  IMT has been proposed as a quantitative index of atherosclerosis of 
value in monitoring disease progression and the effects of treatment and as a surrogate end 
point in clinical trials.  The validity of IMT for these purposes has been assessed by making 
comparisons  of  mean  IMT  in  people  with  and  without  clinical  evidence  of  CVD  and 
discriminatory ability has been demonstrated.  Epidemiological studies, which are less prone to 
bias  inherent  in  clinical  case  series,  have  reported  associations  between  a  range  of 
cardiovascular risk factors (smoking, blood pressure, elevated blood cholesterol) and IMT. Age 
is one of the most powerful determinants of IMT, with increases of from 0.01 to 0.02 mm per 
year and consequently may confound comparisons of IMT made between groups if appropriate 
age adjustment is not made84.
Reported  findings  have  demonstrated  inconsistent  associations  between  IMT,  risk 
factors  and  clinical  disease  and have  also  highlighted  the  importance  of  the  presence  and 
severity of arterial wall plaque as determinants of clinical events.  Some of this variation in 
findings is likely to be due to the method of measuring IMT: mean bifurcation, mean bulb 
origin, mean common carotid, mean internal carotid, and combinations of these.  Correlations 
between  these  different  approaches  are  reported  to  be  high.   It  has  been  suggested  that 
measurement  of  IMT  at  the  “common  carotid  artery  alone,  particularly  for  studies  of 
association of risk factors with carotid arterial disease, cohort studies or clinical trials, in that it, 
too, is associated with the status of coronary atherosclerosis” is a reasonable alternative to more 
detailed and technically difficulty measurement at other sites.  However, plaque formation is 
not common in the common carotid artery.  Since thicker IMT bifurcation and bulb origin 
values tend to occur in people  who also have plaques, it is possible that presence or absence of 
plaque, and not IMT at either the common carotid or bifurcation sites, is the more relevant 
indictor of early atherosclerosis                          
                          
MATERIALS AND METHODS
MATERIALS AND METHODS
SETTING
 Patients  attending  the   department  of  Internal  medicine  and   department  of  Nephrology, 
Madras Medical College  and Government General Hospital,  Chennai 
COLLABORATION DEPARTMENTS
Institute of Internal Medicine
Department of Nephrology
ETHICAL APPROVAL
Institute Ethical Committee approved the study
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STUDY DESIGN
Single Center
Non randomized cross sectional study
DURATION OF STUDY
February 2009 to December 2009
SELECTION OF PATIENTS
Inclusion Criteria
CKD patients  getting  treated  at  Nephrology  department  and  Department  of  Internal 
Medicine, Government General Hospital with stage 2, 3, and 4.
Exclusion Criteria
1. CKD stage 1 & 5
2. Patients with nephrotic syndrome
3. Patients on statins
SAMPLE SIZE
In the study period of 11 months among the patients seen under the Department of Internal 
medicine and nephrology, after applying inclusion criteria, 60 patients were included in this 
study. 
SELECTION OF STUDY SUBJECTS
The patients  who were diagnosed as chronic kidney disease based on the National Kidney 
Foundation definition. 
CONSENT
All participates gave informed consent.
METHODOLOGY
Patients  who  were  included  in  the  study  were  asked  for  the  history  of  diabetes  mellitus, 
hypertension,smoking,intake of  alcohol  and  hyperlipidemia.   pulse  rate  and blood pressure 
were  taken.   Height  and  weight  were  measured  for  body  mass  index  calculation.   The 
information was entered based on the proforma prepared.  Patients are subjected to carotid 
Doppler for measuring carotid intimal medial thickness.  Urine sample for urine protein and 
blood  samples  for  hemoglobin,  hematocrit,  urea,  creatinine,  fasting  blood  sugar,  calcium, 
phosphorus, albumin, fibrinogen, lipid profile are collected and subjected to biochemical tests.
STATISTICAL ANALYSIS
Excel and SPSS 12 were used for data analysis
CONFLICT OF INTEREST
None
RESULTS
                       RESULTS AND OBSERVATIONS
POPULATION CHARACTERISTICS
Among the 60 patients included in the study, 45 (75%) were males and 15 (25%) were females. 
Among 60 patients, 25(41.7%) were in 25 -45yrs, 30(50%) were in 45 -65 yrs, 5 (9.3 %) were 
in >65 yrs age groups.       
TABLE1. AGE AND SEX DISTRIBUTION OF THE STUDY                
                 POPULATION
AGE 
GROUP 
in Years
TOTAL PERCENTAGE MALE FEMALE
25-45 25 41.7 20 5
45-65 30 50 22 8
  
>65 5 9.3 3 2
TABLE 2
CORRELATION OF CIMT WITH AGE 
    35
     
  
    
 
P=0.55. 
Correlation  of 
CIMT with age is not statistically significant
TABLE -3
CORRELATION OF CIMT WITH SEX
P=0.75
Correlation of CIMT with sex is not statistically significant.
AGE
In years
C I M T
<=0.89
mm
>0.89
mm
Total
25 – 45 11 14 25
45 – 65 9 21 30
>65 2 3 5
Total 22 38 60
SEX
C I M T
<=0.89
mm
>0.89
mm
Total
MALE 17 28 45
FEMALE 5 10 14
Total 22 38 60
TABLE 4
CORRELATION OF CIMT WITH SEX   WITH eGFR 
P=<.001
Correlation of CIMT with eGFR is  statistically significant.
      
EDUCATIONAL STATUS
In our study, 38 (63.33%) patients were illiterates, 4(6.66%) had primary education, 16 
(26.66%) had secondary education, while the rest, 2 (3.3%) were graduate.
DIABETES MELLITUS IN THE STUDY POPULATION
 Out of 60 patients in our study, 30 (50%) had diabetes mellitus, of 
  which were 22 (73% )were males and 8(26.6 %) were females.
eGFR
C I M T
<=0.89
mm
>0.89
mm
Total
60-90 6 18 24
30 – 60 6 18 24
15 – 30 10 2 12
Total 22 38 60
TABLE 5
COMPARISON OF CAROTID INTIMAL MEDIAL THICKNESS
IN DIABETIC AND NON DIABETIC
P=.59
Correlation of CIMT with diabetes is not  statistically significant.
HYPERTENSION IN THE STUDY POPULATION
                In our study 32 (53.33%) patients had hypertension, of which, 26(86.66%) 
were males and 6(13.33%) were females.
C I M T
<=0.89
mm
>0.89
mm
Total
DIABETIC 12 18 30
NON-DIABETIC 10 20 30
Total 22 38 60
  TABLE 6
COMPARISON OF CAROTID INTIMAL MEDIAL THICKNESS
IN HYPERTENSIVE AND NON HYPERTENSIVE 
P=.38
Correlation of c IMT with hypertension  is not  statistically significant.
FAMILY HISTORY OF CVD:
           Of the 60, 16 (26.66%) patients were with  family history of CVD,
Of which 14 (87.5%) were males and 2(12.5%) were females . 
ALCOHOLISM IN THE STUDY POPULATION
    Among 60 patients,19(31.67%) were alcoholics.All were males.
TABLE 7
C I M T
<=0.89
mm
>0.89
mm
Total
HYPERTENSIVE 13 18 31
NON-HYPERTENSIVE 9 20 29
Total 22 38 60
COMPARISON OF CAROTID INTIMAL MEDIAL THICKNESS
AMONG ALCOHOLIC AND NON-ALCOHOLIC
 
 
P=.55
Correlation of CIMT with Alcoholism  is not  statistically significant.
     
SMOKING  IN THE STUDY POPULATION:
                 Among 60 patients 26(43.33%) were smokers All were males.
TABLE- 8
COMPARISON OF CAROTID INTIMAL MEDIAL THICKNESS
AMONG SMOKERS AND NON-SMOKERS 
C I M T
<=0.89
mm
>0.89
mm
Total
ALCOHOLIC 8 11 19
NON-ALCOHOLIC 14 27 41
Total 22 38 60
C I M T
<0.89
mm
>0.89
mm
Total
SMOKERS 10 12 22
NON-SMOKERS 12 26 3
Total 22 38 60
                   
P=.55
Correlation of CIMT with Smoking  is not  statistically significant.
DYSLIPIDEMIA AMONG STUDY POPULATION:
PREVALENCE OF HYPERLIPIDEMIA IN CHRONIC KIDNEY DISEASE 
TABLE 9
P=.60
Correlation of eGFR with  serum LDL  is not  statistically significant.
TABLE 10
LDL
mg/dl
eGFR
60 – 90 30 – 60 15 – 30
Total
<130 7 10 12 29
>=130 5 14 12 31
Total 12 24 24 60
HDL
mg/dl
eGFR
60 – 90 30 – 60 15 – 30 Total
<=40 7 11 13 33
>40 5 13 11 27
Total 12 24 22 60
    P=.74
Correlation of eGFR with serum HDL  is not  statistically significant.
TABLE 11
COMPARISON OF CIMT WITH CHOLESTEROL LEVEL
P=.55
Correlation of CIMT with  serum cholesterol is not  statistically significant.
TABLE 12
COMPARISON 
OF CIMT 
WITH LDL 
LEVEL
P=.46
Correlation of CIMT with serum LDL is not statistically significant.
TABLE 13
COMPARISON OF CIMT WITH TRIGLYCERIDES  
P=.87
TOTAL CHOLESTEROL 
LEVEL
mg/dl
C I M T
<=0.89
mm
>0.89
mm
Total
<=240 15 23 38
>240 7 15 22
Total 22 38 60
LDL
mg/dl
C I M T
<=0.89
mm
>0.89
mm
Total
<130 12 17 29
>=130 10 21 31
Total 22 38 60
TGL
mg/dl
CI M T
<=0.89
mm
>0.89
mm
Total
<=150 5 8 13
>150 17 30 47
Total 22 38 60
Correlation of CIMT with serum TGL is not  statistically significant
TABLE 14
COMPARISON OF CIMTWITH HDL 
P=.204
Correlation of CIMT with serum HDL  is not  statistically significant.
HEMOGLOBIN IN THE STUDY POPULATION
               The mean hemoglobin in the study population was 8.97±1.44 g/dl. Anemia 
(hemoglobin 
less than 
10g/dl) was 
present in 
47 (78%) 
while 13 
(21.67%) 
had 
hemoglobin more than 10g/dl.
TABLE 15
PREVALENCE OF ANEMIA
HDL
mg/dl
CI M T
<=0.89
mm
>0.89
mm
Total
<=40 9 22 31
>40 13 16 29
Total 22 38 60
Hb
Mg/dl
eGFR
60 – 90 30 – 60 15 – 30 Total
<=10 4 21 22 47
>10 8 3 2 13
Total 12 24 24 60
P<.001
Correlation of Hemoglobin with eGFR   is  statistically significant.
TABLE 16
CORRELATION OF CAROTID INTIMAL MEDIAL THICKNESS
WITH ANEMIA 
P<.001
Correlation of CIMT with  Hemoglobin  is  statistically significant.
Hb
mg/dl
CI M T
<=0.89
mm
>0.89
mm
Total
<=10 12 35 47
>10 10 3 13
Total 22 38 60
S. PHOSPHATE IN THE STUDY POPULATION 
 
Mean 
S.Phosphate 
of  the  study 
population  is 
4.33±.78, varying within a range of 3.1 -6.9. S.Phosphate was less than 4.3mg/dl in 
37(61.67 %.) and more than 4.3mg/dl in 23 (38.33%) patients
TABLE 17
PREVALENCE OF HYPERPHOSPHATEMIA 
P=.01
Correlation of serum Phosphate with  eGFR is  statistically significant.
TABLE 18
COMPARISON OF CIMT WITH SERUM PHOSPHATE
Phosphate
mg/dl
eGFR
60 – 90 30 – 60 15 – 30 Total
<4.3 11 16 10 37
>=4.3 1 8 14 23
Total 12 24 24 60
P=.014
Correlation of CIMT With serum phosphate levels   is statistically significant.
TABLE 19
COMPARISON OF CIMT WITH   B.M.I. 
P=.59
Correlation of CIMT With BMI Levels   is not  statistically significant.
TABLE 20
CORRELATION OF CIMT WITH SERUM ALBUMIN  
Phosphate
mg/dl
CI M T
<=0.89
mm
>0.89
mm
Total
<4.3 18 19 37
>=4.3 4 19 23
Total 22 38 60
BMI
CI M T
<=0.89
mm
>0.89
mm
Total
<25 8 16 24
25 – 30 12 16 28
>30 2 6 8
Total 22 38 60
P=.01
Correlation ofC IMT With  Albumin  Levels   is  statistically significant.
TABLE 21
CORRELATION OF CAROTID INTIMAL MEDIAL THICKNESS
WITH SERUM LIPOPROTEIN (a)  LEVELS
Sr.ALBUMIN
C I M T
<=0.89 >0.89
Total
<3 1 1 2
3 – 4 19 35 54
>4 2 2 4
Total 22 38 60
P<.001
Correlation of CIMT With serum lipoprotein levels   is  statistically significant.
Sr.LIPOPROTEIN 
(a)
mg/dl
C I M T
<=0.89
mm
>0.89
mm
Total
<30 13 2 15
30 – 60 8 31 39
>60 1 5 6
Total 22 38 60
                  
DISCUSSION
  DISCUSSION
AGE AND GENDER
            In our study of 60 patients with CKD, 75% were males, which are consistent with the 
CKD Registry of India Report where males constituted 68% of the total CKD patients and 
CMC Vellore Study where 62% were males, probably reflect the faster decline in GFR in males 
as compared to females due to hormonal influence. Majority of the patients were in the group 
45-65years,  with a mean age of 50±12.06 years.  The mean age in  CKD Registry  of India 
Report is 48.3±16.6 years and CMC, Vellore study 38.2±14.5 years.
EDUCATIONAL STATUS
             In our study, out of the 60 patients, 71% of the patients were illiterate or just had 
primary education. Though relation of low socioeconomic and educational status with CKD has 
already been found in previous related studies, it cannot be inferred from our study because we 
cater to patients with low socioeconomic status.
FAMILY HISTORY OF CVD
              Family history of CVD was present 26.6% patients.
HABITS AND CKD
             Cigarette smoking was prevalent in 43.33%, alcohol consumption in 31.67%, which 
might have contributed to the faster progression of the disease in these patients whereas the 
CKD  Registry  of  India  Report,  shows  cigarette  smoking  was  prevalent  in  32%,  alcohol 
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consumption in 6.4%
DYSLIPEMIA: 
Mean total cholesterol is 223.09 ± 51.14 mg/dl. Mean LDL is 141±44mg/dl. Mean TGL 
is 190±45 mg/dl. Mean HDL is 40±5 mg/dl 38 (63.33%) patients have total cholesterol levels 
<240 mg/dl and 22(36.6%)have >240mg/dl 
29(48.33%) patients have LDL levels < 130 mg/dl and 31(51.67%) have >130 mg/dl. 
13(21%) patients have TGL levels <150 mg/dl and 47 (79.33%) have >150mg/dl. 31 (51.67%) 
patients have HDL levels <40 mg/dl and 29(49.33%) have >40 levels
There is no significant correlation observed between altered lipid levels 
and e GFR
BODY MASS INDEX:
              Mean BMI is 25.9 ±3.6.
24 (40%) patients have BMI < 25, 28 (46.67%) have between 25 and 30, 8 (13.33%) have > 
30.I n our study there is no significant correlation between BMI and IMT.
SERUM  LIPOPROTEIN a :
          Mean serum lipoprotein a level is 39.6±13. mg/dl. Normal is < 30 mg/dl
        15 (25 %) have levels < 30 mg /dl, 39 (65 %) have levels 30 – 60 mg/ dl and 6 (10 %) 
have > 60 mg /dl.
          There is highly significant correlation between lipoprotein a levels with IMT and e GFR. 
Studies concerning the effect of LPa on IMT of normal persons showed various results. Sramek 
et  al  found  no  increased  IMT  in  the  carotid  or  femoral  artery  at  high  levels  of  LPa  in 
asymptomatic men and concluded that LPa level was not associated with early atherosclerotic 
vessel wall changes in the carotid or femoral arteries.  Dentil et al, in a study on elderly subjects 
(mean age 78 years), showed no association between carotid IMT and LPa and concluded that 
the  LPa was unrelated to  the  severity  of  atherosclerosis  in  the  extra  cranial  vessels,  while 
Baldassarre et al found increased IMT of carotid in hypercholesterolemic patients with plasma 
LPa  levels  >  30  mg/dl  than  in  those  with  moderate  hypercholesterolemia  or 
normocholesterolemic subjects. Finally, Raitakari suggested no association between IMT and 
LPa in healthy subjects but found significant positive correlation with total cholesterol, LDL-C, 
LDL/HDL ratio, age, and triglycerides
SERUM ALBUMIN LEVELS:
 4 (6.67%) have albumin levels > 4gm/dl,  54 (90%) have levels between 3-4 gm/dl and 2 
(3.33%) have < 3gm /dl.
    In our study there significant correlation between serum albumin levels and IMT. 
     Beddu et al showed association between Sr. albumin levels and cardio vascular diseases. 
Owen  et  al  showed  hypoalbuminemia  as  a  strong  predictor  of  mortality  in  CKD 
patients.Stenvinkel et al showed increased IMT with hypoalbuminemia.
CAROTID INTIMAL MEDIAL THICKNESS;
             Mean c IMT is 0.917±0.11mm.
22 (36.66%) patients have IMT <.89 mm and 38 (63.33%) have > .89 mm
There is significant correlation between IMT and e GFR.Zhang et al showed IMT .83±23 in 
stage 2 ,.94±.38 in stage 3 and .11±.21 in stage 4 CKD patients.
There is no significant correlation of IMT with age,sex of the patients.
Though we found diabetics,  hypertensives,smokers  and alcoholics  have an increased 
IMT more frequently a significant correlation could not be found.Pascasio et al.  observed a 
large number of vascular plaques in uremia patients and concluded that the process of advance 
atherosclerosis might be started with the commencement of renal failure; he suggested that 
there  are  other  factors  than  HD treatment  to  accelerate  arthrosclerosis. Damjanovic  et  al. 
evaluated IMT of 45 CKD patients found higher mean carotid IMT in HD  than in control 
group; also showed positive correlation of IMT with certain risk factors for atherosclerosis 
(age, duration of dialysis and lipid parameters). Shoji and Hojs et  al shows only significant 
determinant  of  number  of  plaques  and  concluded  that  CKD  patients  had  advanced 
atherosclerosis in the carotid arteries compared with normal subjects.  
Savage et al noted more prevalence of plaque in carotid and femoral artery in HD and 
correlation between femoral artery plaque score and age of the subjects as well as correlation of 
age with IMT of carotid artery. Recently, Kato et al showed a significant correlation of IMT 
with age in HD patients.  Moreover, Papagianni et al showed a positive correlation of plaque 
score with age of the subjects.
           Although there is altered lipid levels in CKD patients, no correlation were found with 
IMT in our study. Patricia et al shows significant increase in IMT with elevated levels. Maria et 
al  showed  increase  in  IMT  with  elevated  total  cholesterol  levels.Zancetti  et  al  found  no 
correlation with any of the lipid parameter
HEMOGLOBIN
          The mean hemoglobin level in the study population was 8.97±1.44g/dl. 47 (78.33%) had 
anemia (cutoff taken as 10g/dl) , while  21.67% had a value more than 10g/dl. Prevalence of 
anemia increased from Stage 2 to stage 4 and the correlation was statistically significant. This 
is consistent with the CKD Registry of India Report77 where anemia was present in 32.6% of 
Stage 3, 57.5% of Stage 4 and 83.2% of Stage 5 patients.  
    There is positive correlation between hemoglobin levels and IMT.
SERUM.PHOSPHATE
 The  mean  S.Phosphate  level  in  the  study  was  4.33±0.78mg/dl.   37  (61.67%)  had 
S.Phosphate below value   of 4.3mg/dl. while 23 (38%) had a value more than 4.3mg/dl. Mean 
S.Phosphate  level  increases  from stage  2  to    stage  4  and  there  is  statistically  significant 
correlation between S.Phosphate levels and eGFR which is consistent with the observations in 
CKD Registry of India Report77 where mean S.Phosphate levels were 4.54mg/dl in Stage 3, 
4.93mg/dl in Stage 4 and 5.91mg/dl in Stage 5.The percentage of patients with S.Phosphate 
more than or equal to 4.3mg/dl increased from 55.5% in stage 3 to 66.67% in stage 4 to 93.55% 
in stage 5.
There is a significant correlation between serum phosphate levels and IMT.  Ishimura et 
al show that in addition to advanced age, greater serum phosphate level is a significant and 
independent factor associated with advanced arteriosclerosis in CKD patients with and without 
diabetes,  suggesting that  phosphate  levels  should be  controlled appropriately  to  prevent  an 
increase in arterial wall thickness in such  patients. 
The key focus should be the early detection and prevention of progression of CKD at 
stages  1  and  2  using  established  and  emerging  therapies.  Cardiovascular  risk  factor 
identification and management may depend on CKD staging. Special focus on non-traditional 
risk  factors  in  CKD  stages  3-5  may  be  appropriate  in  addition  to  traditional  risk  factor 
modification initiated in CKD stages 1 and 2. Lastly, there is a need to disseminate information 
to  primary  care  providers  who may be key  players  in  initiating and maintaining  the  most 
appropriate  management  strategies.  For  those  with established CVD and CKD that  require 
intervention, the increased risks must be considered and addressed
 To  execute  a  change  in  the  management  of  patients  with  CKD,  medical  students, 
healthcare professionals, and established physicians, need to be educated about the prevalence 
and consequences of CKD. The concept that CKD is a risk factor for cardiovascular disease, 
and needs to be managed should be emphasized. Screening of the high risk individuals (those 
with  hypertension,  diabetes  mellitus,  cardiovascular  disease  and  first  degree  relatives  of 
patients with hypertension, diabetes mellitus or renal disease) will maximize the detection of 
CKD and benefit a large population of patients. 
LIMITATIONS
1. Most of the patients attending the centre of the study belong to the            low 
socioeconomic and educational  status  and hence are  not  an               accurate 
representation of the general population.
2. Etiological  diagnosis was not taken into account
3. B mode ultrasonography method liable to inter observer variation.
4. Presence of atherosclerosis was not confirmed by angiogram.
5. Hypoalbuminemia is a non specific marker of micro inflammation and is elevated in 
systemic lupus erythematosus, rheumatoid arthritis and liver diseases. 
6. This is a cross sectional study where follow up of the patients is not possible.     
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CONCLUSION
CONCLUSION
High prevalence of traditional risk factors like diabetes,hypertension,smoking ,increased 
BMI ,dyslipidemia and non traditional risk factors like anemia, elevated phosphate 
levels,hypoalbuminemia and lipoprotein (a) in Chronic     kidney disease patients  in the study 
population.
1. More than half of the patients were illiterates and one fourth patients give family history 
of CVD.
2. Complications like anemia and hyperphosphatemia increased with     progression of 
stage of chronic kidney disease.
3. Significant  correlation  between  IMT  with  serum  phosphate  levels,  anemia, 
hypoalbuminemia, e GFR, serum lipoprotein (a) levels were noted.
4.  Lipoprotein (a) as a non traditional risk factor in progression of atherosclerosis could 
play  an  important  role  in  accelerating  progressive  atherosclerosis  observed  in  CKD 
patients which needs more attention.
5.  Carotid IMT is a strong predictor of cardiovascular disease in CKD patients and may be 
usefully applied for risk stratification in this group of patients.
 7. Correlation between IMT and dyslipidemia could not be established in the study.
8.  Association  of  IMT  with  DM,  HT,  smoking,  alcoholism  and  obesity  could  not  be 
correlated significantly in this study. 
9 Identifying modifiable risk factors for the progression of cardiovascular disease may lead 
to targeted medical interventions in high-risk groups.
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APPENDIX
ABBREVIATIONS
PROFORMA
MASTER CHART
ETHICAL COMMITTEE APROVAL
    ORDER
                                     ABBREVIATIONS
CKD - Chronic Kidney Disease
ESRD - End Stage Renal Disease
eGFR - estimated Glomerular Filtration Rate
MDRD - Modified Diet in Renal Diseases
NKF/KDOQI - National Kidney Foundation/ Kidney Disease 
Outcome Quality Initiative
NHANES - National Health And Nutritional Examination 
Survey
C IMT - carotid intimal medial thickness
CVD - Cardiovascular Disease
LVH - Left Ventricular Hypertrophy
DM - Diabetes mellitus
AC - Arteria Carotis
LPa - Lipoprotein (a)

PROFORMA 
Name  :     Age :  Sex : 
Occupation :     Education: 
Duration of Disease: 
History of Angina / MI / Stroke / PVD : 
Past H/O : DM / HT : 
Smoking   : Yes / No   Pack years: 
Alcohol  : Yes / No 
Family H/o CVD : Yes / No 
Hyperlipidemia : Yes / No 
Diagnosis  : 
PR : BP : Ht :  Wt :  BMI : 
INV 
Hb    Hematocrit 
Urea 
Creatinine 
FBS 
Calcium   Phosphorus 
Sr.Albumin   Sr.Fibrogen    Sr.Lipoprotein 
Lipid Profile 
Urine Protein 
ECG    ECHO 
Carotid Intimal medial thickness 
 
S.
N
o
N
am
e
A
ge
 
Se
x
E
du
ca
tio
n
H/O
D
M H
T
A
lc
oh
ol
ic
Sm
ok
er
Fa
m
ily
 H
/O
 
C
V
D
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1 SRINIVASAN 70 M ILLITERATE   - - - 160 97 138
2 SELVAM 41 M ILLITERATE -    - 242 162 180
3 NAGULAN 50 M 5th STD -    - 217 127 197
4 ANANDAN 40 M XII STD  - -  - 320 220 292
5 NAYAGAN 61 M ILLITERATE   - - - 272 192 181
6 KUMAR 38 M B.Sc., -     182 96 156
7 MARIMUTHU 60 M ILLITERATE - -    221 145 180
8 ELLAMMAL 52 F ILLITERATE   - - - 206 106 172
9 PADMA 40 F ILLITERATE -  - -  242 162 160
10 VATHANAI 34 F ILLITERATE  - - - - 211 152 182
11 MUNIRATNAM 62 M ILLITERATE      215 139 190
12 ARJUNAN 32 M X STD -  - - - 180 128 182
13 AJAY 45 M XII STD      277 209 188
14 THOMAS 55 M ILLITERATE  - - - - 160 83 132
15 SAMYNATHAN 50 M ILLITERATE   - -  217 163 197
16 SARAVANAN 51 M X STD - - - - - 320 230 268
17 RAMANI 43 F ILLITERATE  - - - - 244 159 172
18 NARAYANASAMY 61 M ILLITERATE      206 141 161
19 PONNURANGAM 80 M X STD - - - - - 292 208 260
20 SELVAM 40 M ILLITERATE - -    242 130 163
21 RAMALINGAM 55 M ILLITERATE      150 92 227
22 PAPPATHY 61 F ILLITERATE - - - - - 250 141 200
23 BABU 50 M X STD - - - - - 210 136 141
24 MAHENDRAN 45 M ILLITERATE  - -   192 106 132
25 ESAKKIMUTHU 55 M XII STD   - - - 252 192 152
26 ARUNACHALAM 40 M ILLITERATE - - - - - 162 92 152
27 SELVARAJ 55 M X STD - -    250 120 163
28 RAJAVEL 45 M ILLITERATE  - - - - 211 120 171
29 PAPPAMMAL 75 F ILLITERATE   - - - 176 107 89
30 PASUPATHY 56 M ILLITERATE   - - - 196 105 124
31 KAREEM 70 M VIII STD - - -  - 241 165 180
32 MAHALAKSHMI 45 F ILLITERATE -  - - - 192 107 198
33 SAMPTH KUMAR 45 M ILLITERATE   -   240 170 151
34 RAJALAKSHMI 46 F X STD - - - -  191 121 158
35 DHANALAKSHMI 65 F ILLITERATE   - - - 310 220 250
36 RAJAN 33 M IX STD -  -  - 142 96 121
37 PAPPV 57 M ILLITERATE - - - - - 148 82 120
38 JAGAN 33 M ILLITERATE - -    212 92 181
39 AYYAPPAN 60 M ILLITERATE -  - - - 340 216 210
40 SANGEETHA 33 F ILLITERATE - - - - - 191 110 154
41 PALAYAM 55 F ILLITERATE - - - - - 138 82 114
42 SARASWATHI 56 F VIII STD  - - - - 212 96 191
43 ESAKKIMUTHU 59 M X STD  -    314 220 280
44 SRIDHAR 26 M B.Com., - - -  - 291 190 202
45 XAVIER 33 M ILLITERATE -    - 310 222 210
46 RAJENDRAN 55 M ILLITERATE  - - - - 240 140 180
47 BALAKRISHNAN 54 M X STD     - 190 121 140
48 BALAN 55 M ILLITERATE -  - - - 230 192 160
49 SRINIVASAN 45 M ILLITERATE      250 208 152
50 CHELLIAH 56 M ILLITERATE -  - - - 226 192 164
51 DURAIKANNU 45 M ILLITERATE - -   - 240 163 186
52 SUBBULAKSHMI 65 F ILLITERATE  - - - - 190 119 142
53 LAKSHMI 56 F ILLITERATE   - - - 250 177 189
54 BALAN 66 M ILLITERATE -    - 126 80 137
55 SEKAR 42 M X STD -    - 165 73 329
56 ZAHEER BASHA 60 M ILLITERATE  -   - 240 110 190
57 ETHIRAJ 57 M ILLITERATE   -  - 280 110 245
58 RAMANI 38 M XII STD  - - - - 125 152 229
59 DHANALAKSHMI 35 F V STD  - - - - 246 110 202
60 KALLAPPAN 25 M X STD -  - - - 240 109 140
